Aptose to Report Third Quarter 2023 Financial Results and Hold Conference Call on Thursday, November 9, 2023
October 26, 2023 07:11 ET
|
Aptose Biosciences, Inc.
Aptose to Report Third Quarter 2023 Financial Results and Hold Conference Call on Thursday, November 9, 2023
Aptose to Hold Clinical Update and KOL Data Review of AML Drug Tuspetinib on Monday, October 30th
October 23, 2023 07:30 ET
|
Aptose Biosciences, Inc.
Aptose to Hold Clinical Update Webcast and KOL Data Review of AML Drug Tuspetinib on Monday, October 30th
Aptose Announces Closing of $3 Million Investment by Hanmi Pharmaceutical
September 06, 2023 07:45 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
Aptose Reports Results for the Second Quarter 2023
August 10, 2023 16:02 ET
|
Aptose Biosciences, Inc.
─ CRc Response Rate 50% with Tuspetinib/Venetoclax Doublet in Evaluable Patients ─ ─ CRc 44% in Patients Who Failed Prior Venetoclax ── CRc 43% in Patients with Wildtype FLT3 ── CRc 67%...
Aptose to Report Second Quarter 2023 Financial Results and Hold Conference Call on Thursday, August 10, 2023
July 27, 2023 16:04 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, July 27, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted...
Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance
June 26, 2023 16:05 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, June 26, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
Aptose to Hold Interim Clinical Update Webcast on Saturday, June 10, 2023
May 31, 2023 07:30 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, May 31, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
Aptose Enters into $25 Million Committed Equity Facility
May 25, 2023 16:14 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, May 25, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
Aptose Biosciences Announces Results of Annual and Special Meeting of Shareholders
May 23, 2023 17:30 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, May 23, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...